Open Access Week (The 5th SPARC Japan Seminar 2009) An open access business model: past and future of BioMed Central (Charlotte Hubbard)

Agenda • BioMed Central, an introduction Open access publishing at p p g • Bi M d C t l’ b i BioMed Central’s business model d l BioMed Central • Growth of BioMed Central Charlotte Hubbard • Acquisition by Springer q y p g Journal Development Manager • Looking forwards BioMed Central Open access at BioMed Central • Largest publisher of peer-reviewed open • Research articles are universally available access journals via the Internet, without any barriers to y access • 200+ journals • C Copyright li i ht license allows redistribution and ll di t ib ti d • >55,000 open access articles reuse as long as attribution is given • ~5 million articles accessed/month • Permanently archived in internationally • I Immediate, b i f di t barrier-free open access t to recognised repositories (e g PubMed (e.g. research Central)

Our journals • BMC-series (~60 titles) – Largely in-house editorial processes – Broad scope • Independent journals (~130 titles) BioMed Central’s business model – Run by external groups of scientists or societies – Niche or broad scoped as defined by the Editors • Hybrid journals (6 titles) – Publish open access research, and subscription- based reviews and commentary New technologies change practices New technologies change business and business models models Traditional model Open access model • Research community y • Research community y transfers rights to the retains ownership of research to the the work publisher • The publisher sells the • The publisher charges research back to the directly for the service community of dissemination/ publication

BioMed Central revenue streams • Publication fees (80-90%) • S b i ti content (‘h b id j Subscription t t (‘hybrid journals’) l ’) • Advertising/sponsorship Open access p p publication fees • Services (e.g. Open Repository) ( g p p y) What do they cover? How much are we charging? • The costs of running open access journals • Standard charge is £925 / US$1535, ~¥132,000 are similar to those in traditional journal j publishing: • Charges range from $915 - $2265 – Editorial • Article-processing charge is a flat-fee; there – Production are no additional costs – Technical T h i l – Marketing – Customer services

How does this compare to other Who pays? publishers? • Hindawi $600 - $1500 • Author’s funding body • BioMed Central $915 - $2265 • Author s Author’s institution • PLoS $1300 - $2850 • Direct payment by the authors • Oxford University Press $3000 $ • Charges are waived where there is a genuine inability to pay • Springer p g $ $3000 – O Open access waiver f d supported b Pfi i fund, t d by Pfizer • Wiley $3000 • Taylor F T l & Frances $3250 • S Supplements may be f d d b conferences or l t b funded by f • Cell Press $5000 sponsors BioMed Central membership BioMed Central membership • Prepay membership • ~300 members worldwide Institution covers the cost of publication centrally at a discounted rate • Supporter membership pp p Institution pays a low-rate, flat fee and authors receive a discount (15%)

Not all our journals charge APCs Rejection rate and open access • Chinese Medicine Chi M di i • High prestige journals tend to have high • Chiropractic & Osteopathy rejection rates j • Italian Journal of Pediatrics • Journal of Biomedical Science • Lots of submissions, relatively few • Journal of Brachial Plexus and Peripheral Nerve Injury publications • Journal of Orthopaedic Surgery and Research • Journal of the International AIDS Society • How to make this economically viable? • Scandinavian Journal of Trauma Resuscitation and Emergency Medicine • Sports Medicine, Arthroscopy, Rehabilitation, Therapy & Technology Journal peer review cascade High rejection rate Moderate M d Other sources of revenue rejection rate Low rejection rate

Journals with subscription content Advertising/sponsorship • All research articles are open access • Subscription for reviews and commentaries Additional services A hosted solution that builds and maintains repositories on behalf of organisations Growth of BioMed Central

Annual submissions Annual submissions from Japan 30000 900 25000 800 700 20000 600 500 15000 400 10000 300 200 5000 100 0 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 Number of journals Number of journals • Steady growth of the portfolio from 59 journals • Two new publishing platforms: to 200 – 3 have Japanese Editors-in-Chief • Increasingly established titles are choosing to move to BioMed Central

Journals choosing to transfer Acta Veterinaria Scandinavica 150 1 0.8 Subm issions Impa factor 0.6 act m 0.4 0.2 0 0 2004 2005 2006 2007 2008 2006 2007 2008 2009 Year Year Year of transfer High visibility • No barriers to access • Easily available to all aggregators/indexers Key drivers of g y growth

Building off success in key areas Building on success in key areas • Bioinformatics • Genomics • Cancer • Public Health Providing a good service to authors Providing a good service to authors Surveyed authors: • Updating technologies to meet our authors • 95% rate our online submission system as q requirements ‘Good’ or ‘Very good’ • 90% would recommend publishing in a BioMed Central journal to a colleague j g • 90% rate the experience of publishing with BioMed Central as ‘G d’ or ‘ dC l ‘Good’ ‘Very G d’ Good’ Embedded movies and mini-websites

Marketing Marketing Marketing Impact factors

Number of journals with impact factors Growing momentum of open access 60 2000 2009 50 40 30 20 10 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 …and more and Growing momentum of open access Growing momentum of open access • Mandatory open access deposit policies from: – Funding bodies, e.g. NIH, HMMI, UK Wellcome Trust – Institutes, e.g. Harvard, MIT, UCL • Central funding from institutions – Berkeley, Calgary, Harvard, Nottingham, Newcastle

Growing momentum of open access • Many institutes have repositories in place, which can encourage open access g p publication Acquisition b S i A i iti by Springer • BUT there are difficulties in populating these + • Automation of feeds using SWORD protocol What does the acquisition mean for What does the acquisition mean for BioMed Central? BioMed Central? • Acquisition by Springer is a strong • BioMed Central remains an autonomous p endorsement of the success of our open operating unit within Springer p g p g access publishing model • BioMed Central is committed to permanently • Springer’s global infrastructure and market Springer s maintaining our open access p g p policy, y, presence is helping us to expand activities safeguarded by a Board of Trustees

Plans for 2010 and beyond beyond… • Continued growth and development of existing titles g Looking forwards g • New launches planned and continued work with society journals Plans for 2010 and beyond beyond… Plans for 2010 and beyond beyond… • Continue to make the most of new • Continue to work with funding bodies, g technologies: institutions and organisations to advocate g – Planned website redesign open access – Improved PDF rendering – Updates to peer review tools • Expansion of conference activities in support – Hosting translations of our journals and Editors

Summary • BioMed Central operates a successful open access business model Thank you! • We have developed a portfolio of 200 journals, many ranking highly in their Charlotte Hubbard respective fields p Journal Development Manager p g Charlotte.Hubbard@biomedcentral.com • Plans for continued growth and development, assisted b S d l d by Springer’s global ’ l b l infrastructure and market presence

Open Access Week (The 5th SPARC Japan Seminar 2009) An open access business model: past and future of BioMed Central (Charlotte Hubbard)

by Keita Bando on Nov 11, 2009

Accessibility

Categories

Upload Details

Usage Rights

1 Embed 12

Statistics

Open Access Week (The 5th SPARC Japan Seminar 2009) An open access business model: past and future of BioMed Central (Charlotte Hubbard) — Presentation Transcript